FDA Clearance Tracker · P160019-S001
Elecsys HBsAg II/Elecsys HBsAg Confirmatory Test/ PreciControl HBsAg II
Last checked: Nov 20, 2026Latest source record: Nov 1, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Nov 1, 2017
Approved
Time to decision
176 days
Received May 9, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P160019-S001
- Device name
- Elecsys HBsAg II/Elecsys HBsAg Confirmatory Test/ PreciControl HBsAg II
- Applicant
- Roche Diagnostics, Inc.
- Applicant location
- Indianapolis, IN
- Received
- May 9, 2017
- Decided
- Nov 1, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P160019
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for migration of the Elecsys HBsAg II, Elecsys HBsAg Confirmatory Test, and PreciControl HBsAg II to the cobas e 602 immunoassay analyzer.
Source documents
Other decisions for Roche Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P160019 · Decided Dec 23, 2016 · 175 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.